Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
Data ReadoutpositivegiredestrantPositive
AI Analysis
Summary
Roche's giredestrant combination demonstrated significantly improved progression-free survival in Phase III evERA trial for ER-positive advanced breast cancer, with results published in The New England Journal of Medicine.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Significantly improved progression-free survival in Phase III evERA trial
Importance:8/10
Sentiment:
0.85
breast cancerER-positivePhase 3NEJM publicationcombination therapy
Related Companies
Read the original article
Published by yahoo_finance on October 1, 2026 5:00 AM